TokenPost·
Genmab Says Petosemtamab-Keytruda Combo Cut Mortality Risk 50%
The Phase 3 data involved certain patients with head and neck cancer. Petosemtamab is a bispecific antibody therapy.
More news
- Crypto BriefingWEF and BCG report says digital asset regulation now reaches far beyond crypto
- TokenPostU.S. Treasury Sanctions 11 Over North Korean Crypto Laundering Network
- TokenPostBBVA Q3 Consensus Sets Net Attributable Profit Estimate at €3.007 Billion
- TokenPostOCC Publishes Stablecoin Rule With Jan. 18, 2027, Effective Date
- TokenPostTether and Circle Lead Seven-Day Revenue With $169.34 Million
- TokenPostMichael Saylor Compares Stock Tokenization Rejection to Index Exclusion